An Z, Lei T, Duan L, et al. - Among 128 Chinese patients with active acromegaly, researchers assessed the safety and effectiveness of lanreotide autogel compared with lanreotide 40 mg prolonged release (PR). Lanreotide autogel 60/90/120 mg (monthly deep subcutaneous injection) or lanreotide 40 mg PR (intramuscular injection every 7, 10 or 14 days) were treated for 32 weeks in patients with active acromegaly who had undergone surgery ≥ 3 months prior to or were unlikely or unable to undergo surgery. According to this phase 3, randomized, open-label, non-inferiority study, after 32 weeks of treatment, lanreotide autogel (monthly deep subcutaneous injection) was non-inferior to lanreotide 40 mg PR (intramuscular injection every 7, 10, or 14 days) in Chinese patients with active acromegaly. There were no major variations between the treatments for hormonal control, tumor volume, and symptoms of acromegaly.